%0 Journal Article
%T Peptidomic profiles of post myocardial infarction rats affinity depleted plasma using matrix-assisted laser desorption/ionization time of flight (MALDI-ToF) mass spectrometry
%A Bing Wang
%A Simone Reisman
%A Mark Bailey
%A Andrew Kompa
%A Mustafa Ayhan
%A Henry Krum
%A Gregory Rice
%J Clinical and Translational Medicine
%D 2012
%I Springer
%R 10.1186/2001-1326-1-11
%X One week after MI, rats were randomized to receive either an ACE inhibitor (ramipril, Ram-1£¿mg/kg/day), or vehicle (Veh) for 12£¿weeks. Echocardiography and hemodynamic measurements were made before sacrifice and plasma collection. High abundance proteins were depleted with affinity capture before MS profiling. Differentially expressed peptide ions were identified using proprietary software (ClinProtTools).MI increased heart/body weight (18%), lung/body weight (56%), and left ventricular (LV) end diastolic pressure (LVEDP, 247%); and significantly reduced percentage fractional shortening (FS, 75%) and rate of pressure rise in the LV (dP/dtmax, 20%). Ram treatment significantly attenuated the changes in LVEDP (61%) and FS (27%). Analysis of MALDI-ToF generated mass spectra demonstrated that peptide ions 1271, 1878, 1955, 2041 and 2254£¿m/z were consistently decreased by Ram treatment (p£¿<£¿0.001) and thus may be associated with the agent¡¯s therapeutic effects. Among peptides that were significantly changed, synapsin-2, adenomatous polyposis coli protein and transcription factor jun-D were identified as significantly reduced by Ram treatment.This approach allows us to screen for potential biomarkers in a window of the blood proteome that previously has been difficult to access. The data obtained from such an approach may potentially useful in prognosis, diagnosis, and monitoring of treatment response.Despite the advancesment in the development of effective therapies for cardiovascular diseases (CVDs), their socioeconomic and human costs continue to escalate throughout the world, with an aging population. The number of effective cardiovascular therapies and viable therapeutic targets remains surprisingly limited. The number of clinically useful cardiovascular biomarkers is even fewer [1]. As most CVDs directly impact expression and function of circulating proteins and peptides, the likelihood of identifying CVD-associated changes within this system is significant.Consider
%K Myocardial infarction
%K Peptidomic profiling
%K Mass spectrometry
%K Biomarkers
%K Heart failure
%U http://www.clintransmed.com/content/1/1/11